New stromal target overcomes cancer resistance
British researchers have identified several small molecule drugs that sensitized B cell cancers to chemotherapy and extended survival in mouse models.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1165 entries already.
Entries by Thomas Gabrielczyk
Astellas and Adaptimmune team up in CAR-T development
/in News/by Thomas GabrielczykAdaptimmune Therapeutics plc and Japanese Astellas Pharma, Inc. have signed a discovery partnership to develop off-the-shelf allogeneic T cell-based cancer therapies from stem cells.
Illumina embraces Roche
/in News/by Thomas GabrielczykTwelve years after Roches $6.8bn hostile takeover bid for Illumina, the companies have entered into a 15-year partnership to boost personalised NGS-based cancer testing.
Incyte licenses Morphosys tafasitamab in US$2bn deal
/in News/by Thomas GabrielczykIncyte Corp. has signed a global license agreement for commercialisation of Morphosys AGs anti-CD-19 programme tafasitamab.
Novadiscovery takes off with 5 Series A financing
/in News/by Thomas GabrielczykIn silico clinical trials pioneer Novadiscovery SA has raised 5m in a series A financing led by Swiss Debiopharm Innovation Fund.
Alderaan Biotechnology raise 18.5m in Series A financing
/in News/by Thomas GabrielczykFollowing a 1.5m seed financing in 2017, cancer specialist Alderaan Biotechnology SAS has raised 18.5m in a Series A round led by Advent France Biotechnology and Medicxi.
North Sea Therapeutics raises US$40m in Series B
/in News/by Thomas GabrielczykNorthSea Therapeutics BV has raised US$40m to provide proof-of-concept of its NASH drug icosabutate.
Merck and 4SC collaborate in immunooncology
/in News/by Thomas Gabrielczyk4SC AG and Merck KgaA have signed a supply agreement to start clinical tests of Mercks checkpoint blocker avelumab plus 4SCs HDAC I blocker domatinostat.
Novo Holdings invest US$12m in AMR companies
/in News/by Thomas GabrielczykMutabilis and IBT Vaccines have successfully bagged US$12m from the Novo Holdings REPAIR Impact Fund.
Fighting sepsis mortality
/in News/by Thomas GabrielczykCritical care experts have presented data supporting the thesis that three specific pathways are the cause for about 90% of sepsis mortality.